A different kind of "allogeneic transplant": Successful fecal microbiota transplant for recurrent and refractory Clostridium difficile infection in a patient with relapsed aggressive B-cell lymphoma

Leukemia and Lymphoma

Volumn 56, Issue 2, 2015, Pages 512-514

  Trubiano, Jason A ^a   George, Anupkumar ^a   Barnett, Jennifer ^a   Siwan, Mahendra ^a   Heriot, Alexander ^a   Prince, H Miles ^a,b   Slavin, Monica A ^a,c   Teh, Benjamin W ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FENOFIBRATE; METHOTREXATE; METRONIDAZOLE; PANOBINOSTAT; PREDNISOLONE; RITUXIMAB; VANCOMYCIN; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; AGED; ALLOTRANSPLANTATION; ALTERNATIVE MEDICINE; ANTIBIOTIC THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CENTRAL NERVOUS SYSTEM METASTASIS; CHRONIC KIDNEY FAILURE; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; CONTROLLED STUDY; DIARRHEA; ESSENTIAL HYPERTENSION; FECES MICROFLORA; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; GRAFT RECIPIENT; HISTOLOGY; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LETTER; LOWER RESPIRATORY TRACT INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; SKIN BIOPSY; SKIN DISEASE; TREATMENT DURATION; VERY ELDERLY; ANTIBIOTIC RESISTANCE; B CELL LYMPHOMA; CLOSTRIDIUM INFECTIONS; COMPLICATION; FECAL MICROBIOTA TRANSPLANTATION; HOST PATHOGEN INTERACTION; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PHYSIOLOGY; PROCEDURES; RECURRENT DISEASE; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG RESISTANCE, BACTERIAL; FECAL MICROBIOTA TRANSPLANTATION; HOST-PATHOGEN INTERACTIONS; HUMANS; LYMPHOMA, B-CELL; MALE; NEOPLASM RECURRENCE, LOCAL; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84923873423     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.920503     Document Type: Letter

References (15)

1. Trubiano IA, Worth LJ, Th ursky KA, et al. The prevention and management of infections due to multi-drug-resistant organisms in haematology patients. Br J Clin Pharmacol 2013 Dec 17. [Epub ahead of print]
2. P armar S R, Bhatt V, Yang J, et al. A retrospective review of metronidazole and vancomycin in the management of Clostridium diffi cile infection in patients with hematologic malignancies. J Oncol Pharm Pract 2014; 20: 172-182
3. Gough E, Shaikh H, Manges A. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium diffi cile infection. Clin Infect Dis 2011; 53: 994-1002
4. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium diffi cile infection: a systematic review. J Clin Gastroenterol 2014 Jan 16. [Epub ahead of print]
5. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal donorfeces infusion for recurrent C. difficile. N Engl J Med 2013; 368: 407-415
6. N eemann K, Eichele D D, Smith P W, et al. F ecal microbiota transplantation for fulminant Clostridium diffi cile infection in an allogenic stem cell transplant patient. Transplant Infect Dis 2012; 14: E161-E165
7. Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium diffi cile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2012; 54: 1053-1063
8. Willems L, Porcher R, Lafaurie M, et al. Clostridium diffi cile infection after allogeneic hematopoietic stem cell transplantation:incidence, risk factors, and outcome. Biol Blood Marrow Transplant 2012; 18: 1295-1301
9. Cornely OA, Miller M, Fantin B, et al. Resolution of Clostridium diffi cile-associated diarrhea in patients with cancer treated with fi daxomicin or vancomycin. J Clin Oncol 2013; 31: 2493-2499
10. Louie TJ, Miller MA, Mullane KM, et al.; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium diffi cile infection. N Engl J Med 2011; 364: 422-431
11. Clutter DS, Dubrovskaya Y, Meri MY, et al. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium diffi cile-associated diarrhea. Antimicrob Agents Chemother 2013; 79: 4501-4505
12. Trubiano JA, Gardiner B, Kwong JC, et al. Faecal microbiota transplantation for severe Clostridium diffi cile infection in the intensive care unit. Eur J Gastroenterol Hepatol 2013; 25: 255-257
13. Gallegos-Orozco JF, Paskvan-Gawryletz CD, Gurudu SR, et al. Successful colonoscopic fecal transplant for severe acute Clostridium diffi cile pseudomembranous colitis. Rev Gastroenterol Mex 2012; 77: 40-42
14. Y ou D, Franzos M, Holman R. S uccessful treatment of fulminant Clostridium diffi cile infection with fecal bacteriotherapy. Ann Intern Med 2008; 148: 632-633
15. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium diffi cile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003; 36: 580-585.